Depot-glucagon in the treatment of McArdle's disease.
Glucagon has been reported to improve exercise tolerance in some patients with myophosphorylase deficiency (McArdle's disease) but a placebo effect was not excluded in previous trials. A single-blind controlled trial of glucagon in a patient with myophosphorylase deficiency is described. Although an improved exercise endurance of the forearm muscles was demonstrated with both short-acting and depot-glucagon, this was not statistically significant when compared with placebo or no treatment.
D000328:Adult; D003692:Delayed-Action Preparations; D005260:Female; D005934:Glucagon / Q000008:administration & dosage / Q000627:therapeutic use*; D006008:Glycogen Storage Disease / Q000188:drug therapy*; D006012:Glycogen Storage Disease Type V / Q000188:drug therapy*; D006801:Humans; D009132:Muscles / Q000502:physiology; D010807:Physical Endurance / Q000187:drug effects
D003692:Delayed-Action Preparations; D005934:Glucagon